brivaracetam

Brivaracetam (CAS 357336-20-0) is a racetam derivative of levetiracetam used to treat partial-onset seizures, binding SV2A with roughly 20 times higher affinity than levetiracetam; it is marketed under the brand name Briviact by UCB, which received FDA approval on February 19, 2016. Manufactured directly by Brother Enterprises Holding Co., Ltd to pharmaceutical grade meeting USP, ChP, BP, EP, and JP compendial standards, it is sold into North America.